![Thomas Sabia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Thomas Sabia formerly worked at Quince Therapeutics SpA, as Chief Commercial Officer from 2022 to 2023 and Quince Therapeutics, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Sabia received his undergraduate degree and Masters Business Admin degree from Salisbury State University.
Eerdere bekende functies van Thomas Sabia
| Bedrijven | Functie | Einde |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 28-02-2025 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Corporate Officer/Principal | 01-10-2023 |
Opleiding van Thomas Sabia
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
5
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Salisbury State University
 Salisbury State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
